Where can I buy genuine evantumumab in 2024?

Purchase channels for evantumumab in 2024

1. Hospital pharmacy

Patients can go to the hospital pharmacy to consult and purchase evantumumab. Hospital pharmacies often work with drug suppliers to ensure the quality and reliability of their sources. Patients need to consult their doctor and obtain a suitable prescription before purchasing.

2. Professional pharmacies

Some large pharmacies may also provide evantumumab sales services. Patients can go to designated professional pharmacies to purchase it under the advice of their doctor. Likewise, patients are required to provide a prescription and follow the pharmacist's advice and guidance.

3. Online purchase

On the Internet, some legitimate online pharmacies or pharmaceutical agencies may provide purchase services. Patients can learn about reliable online purchasing channels through search engines or consulting their doctors. When choosing to purchase online, be sure to ensure that the website has legal qualifications to sell medicines, secure payment methods, and a good reputation.

4. Overseas medical service institutions

Patients can also search for regular overseas medical service institutions online. They usually cooperate with domestic and overseas drugs and can help patients obtain drugs and have them delivered to their homes, ensuring they are genuine. However, you need to find a formal and qualified overseas medical service institution to avoid being deceived.

No matter which purchasing method you choose, patients should ensure that they are buying genuine drugs and avoid buying fake and shoddy products. For any questions regarding the purchase or use of medications, patients are advised to consult a professional physician or pharmacist to ensure safe and effective treatment.

For information about the safety of evantumumab, please click: This article has a detailed introduction.

Evantuzumab Efficacy

Evantuzumab remains tolerable and effective in patients with non-small cell lung cancer (NSCLC) who carry EGFR exon 20 insertion mutations and whose disease has progressed after platinum-based chemotherapy, according to long-term data from the phase 1 CHRYSALIS (NCT02609776).

At a median follow-up of 19.2 months, the median progression-free survival (PFS) with evantumumab was 6.9 months, and the 2-year PFS rate was 13.7%. The drug had a median overall survival (OS) of 23 months and a 2-year milestone OS rate of 47.2%.

In addition, according to investigator assessment, the objective response rate (ORR) of evantumumab was 37% and the median duration of response (DOR) was 12.5 months. Notably, the drug's efficacy proved to be consistent regardless of prior treatment or response to prior platinum-based chemotherapy.

Precautions for taking evantumumab

1. Inform patients that evantumumab may cause infusion-related reactions, most of which may occur during the first infusion.

2. Inform patients of the risk of interstitial lung disease (ILD)/pneumonitis. Advise patients to contact their doctor immediately if they develop new or worsening respiratory symptoms.

3. Inform patients of the risk of adverse skin reactions. Patients are advised to limit direct sunlight exposure, use broad-spectrum UVA/UVB sunscreen, and wear protective clothing during treatment with evantumumab.

4. Inform patients of the risk of ocular toxicity. Patients are advised to contact their ophthalmologist if they develop eye symptoms.

5. Inform patients of the risk of paronychia. Advise patients to contact their healthcare provider regarding signs or symptoms of paronychia.

6. Inform women of reproductive potential of the potential risk to the fetus, use effective contraceptive measures during evantumumab treatment and within 3 months after the last dose, and inform the doctor of known or suspected pregnancy.

7. Women are advised not to breastfeed during treatment with evantumumab and for 3 months after the last dose.

Related hot article recommendations: